<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480022</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1198-4126</org_study_id>
    <nct_id>NCT03480022</nct_id>
  </id_info>
  <brief_title>Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS</brief_title>
  <acronym>SAXAPCOS</acronym>
  <official_title>A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing need to develop pharmacologic interventions to improve metabolic function&#xD;
      in women with polycystic ovary syndrome (PCOS). Given that PCOS is a frequent condition and&#xD;
      weight loss is essential but difficult to achieve, it is important to study if the effect on&#xD;
      body weight reported in other studies can be confirmed in a selected population of&#xD;
      hyperandrogenic patients, especially with medications currently approved for weight&#xD;
      reduction. High dose liraglutide alone results in significant weight reduction in obese women&#xD;
      without PCOS. There is limited data on weight loss with high dose liraglutide in non-diabetic&#xD;
      females with PCOS treated with this agent . Studies on the effect of anti-obesity medication&#xD;
      combined with lifestyle changes on body weight and composition and androgen excess in obese&#xD;
      women diagnosed with PCOS are lacking. The investigators aim to elucidate the most&#xD;
      efficacious weight reduction regime in obese PCOS women. The investigators further hope to&#xD;
      determine which treatment(s) addressing the multifaceted disturbances of this disorder in&#xD;
      patients with PCOS and obesity emerges as the preferable therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug, liraglutide 3.0 mg was approved for chronic weight management in management in&#xD;
      obese adults with an initial BMI of 30 kg/m2 or greater or in overweight adults BMI of 27&#xD;
      kg/m2 or greater with at least one weight-related co-morbid condition as an adjunct to a&#xD;
      reduced-calorie diet and increased physical activity. Liraglutide is an acylated human&#xD;
      glucagon-like peptide -1 (GLP-1) analog that binds to and activates the GLP-1 receptor. It&#xD;
      lowers body weight through decreased caloric intake while stimulating insulin secretion and&#xD;
      reducing glucagon via a glucose-dependent mechanism. For obesity management, patients may&#xD;
      lose weight with GLP-1 receptor agonists due to other unique actions. Glucagon-like peptide-1&#xD;
      receptor agonists (GLP-1RAs) can slow gastric emptying and increase satiety. While predictors&#xD;
      of weight loss success for the general population are available (protein intake, weight loss&#xD;
      medications), predictors of weight loss success may differ between normal and hyperandrogenic&#xD;
      women. Glucagon-like peptide 1 agonists are linked with dose dependent weight lowering&#xD;
      potential in different obesity related populations. The weight loss effects of GLP-1RAs&#xD;
      previously demonstrated in diabetic and obese non-diabetic patients, offer a unique&#xD;
      opportunity to expand the medical options available to patients with PCOS.&#xD;
&#xD;
      Given this lack of information, the aim of the present study was to investigate the effects&#xD;
      of liraglutide 3mg vs. placebo on body composition as well as hormonal and metabolic features&#xD;
      in non-diabetic obese women with PCOS.The non-diabetic obese female with PCOS offers a unique&#xD;
      model to study the relationship between insulin resistance and adiposity. The investigators&#xD;
      propose a double-blind, placebo-controlled 30-week trial designed to directly examine the&#xD;
      therapeutic effects of liraglutide 3 mg (LIRA 3 mg) compared to placebo on body weight,&#xD;
      hormonal and cardiometabolic parameters in obese non-diabetic women with PCOS. All patients&#xD;
      will receive diet and lifestyle counseling, including advice on exercise commencing during&#xD;
      the lead-in period and continuing throughout the study. In this study, the investigators will&#xD;
      examine the efficacy of LIRA 3mg on body weight and body composition, reproductive function&#xD;
      metabolic parameters and cardiovascular risk factors in a well-defined group of&#xD;
      pre-menopausal obese non-diabetic women with hyperandrogenism, focusing on the relationship&#xD;
      to obesity and insulin resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">May 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 22, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double- Blind 2:1 Drug: Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Body Weight (BW)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on change in body weight after 32 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Androgen Index (FAI)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Drug treatment effect on free androgen levels as calculated as FAI= total testosterone (T) concentrations divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome (more androgenic).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect in reducing body mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Body Weight</measure>
    <time_frame>Change from baseline (time 0) to study end (32 weeks)</time_frame>
    <description>Treatment effect on reducing body weight expressed as percent body weight loss from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5% Weight Loss From Baseline</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Frequency of patients achieving 5% weight loss from baseline with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10% Body Weight Loss From Baseline</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Frequency of patients with at least 10% reduction in body weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Adiposity (Waist Circumference [WC]</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on loss of WC (abdominal adiposity) with drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Hip Ratio</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Change in central adiposity with treatment as measured by WHR. A reduction in ratio indicates a decrease in truncal fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to Height Ratio [WHtR])</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on loss of central adiposity as determined by WHt ratio. The lower the ratio indicates less abdominal adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fat Mass Evaluated by DEXA</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on reduction of fat mass (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Fat (%) by DXA</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on reduction of percent body fat by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Android-Gynoid Ratio (AGR) by DXA</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on AGR, measure of central adiposity, as determined by DXA. A lower AGR indicates a reduction in central adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trunk/Leg Fat Ratio (TLR) by DXA</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on TLR after 32 weeks. A reduction in TLR indicates a loss of central fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle Frequency</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Drug treatment impact on normalization of cycle frequency (cycle every 28-30 days). All cycle data is expressed as number of menses annualized to one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone Concentrations (T)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Drug treatment effect on total testosterone concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal Dehydroepiandrosterone Sulfate (DHEAS)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment efficacy in reducing adrenal hyperandrogenism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose (FG)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on fasting glucose prior to an oral glucose tolerance test (OGTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT Mean Blood Glucose (MBG)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on MBG measured during the oral glucose tolerance test. A decrease in MBG shows improvement in glycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Sensitivity (HOMA-IR)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on the HOMA-IR which is an insulin resistance measured derived from fasting blood glucose and insulin . The higher the number the more insulin resistant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Insulin Sensitivity Index Derived From the OGTT (SI OGTT)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>The SI OGTT is a measure of peripheral insulin sensitivity derived from the insulin and glucoses measured during an OGTT. A increase in SI OGTTindicates greater insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion- Insulin Sensitivity Index (Oral Disposition Index-IS-SI)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment effect on an estimation of Beta cell compensatory function, the IS-SI is derived by applying the concept of the disposition index to measurements obtained during the 2 hour OGTT and calculated as the index of insulin secretion factored by insulin sensitivity. A higher score shows improved pancreatic beta cell function relative to insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Levels</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on improving total cholesterol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Impact of treatment on HDL levels after 32 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride Levels (TRG)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Drug effect of TRG levels after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride to HDL-Cholesterol Ratio (TRG/HDL-C)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on TRG/HDL-C ratio which is a simple measure to estimate insulin action. A decrease in ratio indicates improvement in insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride and Glucose Index (TyG)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on the TyG index which estimates insulin resistance. A reduction in TyG indicates an improvement in insulin action.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure (BP)</measure>
    <time_frame>32 weeks of treatment</time_frame>
    <description>Treatment impact on reducing diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity Android</condition>
  <arm_group>
    <arm_group_label>Liraglutide Pen Injector (Saxenda)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo liraglutide pen injector</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide Pen Injector [Saxenda]</intervention_name>
    <description>daily sc injection of liraglutide with final dose of 3mg daily</description>
    <arm_group_label>Liraglutide Pen Injector (Saxenda)</arm_group_label>
    <other_name>Liraglutide 3mg</other_name>
    <other_name>Saxenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Liraglutide Pen Injector</intervention_name>
    <description>daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
    <arm_group_label>Placebo liraglutide pen injector</arm_group_label>
    <other_name>Placebo Saxenda</other_name>
    <other_name>Placebo liraglutide 3 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  18-45 years of age&#xD;
&#xD;
          -  BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with one or more obesity-associated co-morbid&#xD;
             conditions (e.g. hypertension, and dyslipidemia)&#xD;
&#xD;
          -  PCOS- NIH criteria hyperandrogenism and irregular menstrual cyclicity&#xD;
&#xD;
          -  Non-diabetic as determined by a 75 gram oral glucose tolerance test (OGTT) and&#xD;
             hemoglobin A1C. Non-diabetic is inclusive of women with impaired fasting glucose&#xD;
             (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT). Participants with diabetes&#xD;
             will be excluded&#xD;
&#xD;
          -  Willing to use effective contraception consistently during therapy which is defined&#xD;
             as:&#xD;
&#xD;
               -  an intrauterine device, tubal sterilization, or male partner vasectomy, or&#xD;
&#xD;
               -  combination of two barrier methods with one being male condom.&#xD;
&#xD;
          -  Written consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of significant systemic disease, cerebrovascular disease, clinically&#xD;
             significant cardiac abnormalities or heart problems including congestive heart&#xD;
             failure, unstable angina or acute myocardial infarction, current infectious liver&#xD;
             disease, acute stroke or transient ischemic attacks, history of pancreatitis, or&#xD;
             diabetes mellitus (Type 1 or 2)&#xD;
&#xD;
          -  Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic&#xD;
             hepatic damage, jaundice of unknown etiology) or severe hepatic insufficiency and/or&#xD;
             significant abnormal liver function tests defined as aspartate aminotransferase (AST)&#xD;
             &gt;3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          -  Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR &lt;60&#xD;
             mL/min/1.73 m2) or history of unstable or rapidly progressing renal disease or end&#xD;
             stage renal disease.&#xD;
&#xD;
          -  Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital&#xD;
             adrenal hyperplasia or clinically significant elevations in prolactin levels. The&#xD;
             clinical significance of prolactin levels will be determined by the treating physician&#xD;
&#xD;
          -  Significantly elevated triglyceride levels (fasting triglyceride &gt; 400 mg %)&#xD;
&#xD;
          -  Untreated or poorly controlled hypertension (sitting blood pressure &gt; 160/95 mm Hg)&#xD;
&#xD;
          -  Use of hormonal medications, the use of medications that cause clinically significant&#xD;
             weight gain or loss (prescription or OTC) and medications known to exacerbate glucose&#xD;
             tolerance (such as isotretinoin, hormonal contraceptives, GnRH analogues,&#xD;
             glucocorticoids, anabolic steroids, C-19 progestins) including herbal medicines for at&#xD;
             least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as&#xD;
             5-alpha reductase inhibitors (finasteride, spironolactone, flutamide) for at least 4&#xD;
             weeks&#xD;
&#xD;
          -  Prior history of a malignant disease requiring chemotherapy&#xD;
&#xD;
          -  Family or personal history of familial medullary thyroid carcinoma or multiple&#xD;
             endocrine neoplasia type 2&#xD;
&#xD;
          -  Known hypersensitivity or contraindications to use GLP1 receptor agonists&#xD;
&#xD;
          -  Use of metformin, thiazolidinediones, GLP-1 receptor agonists, dipeptidyl peptidase-4&#xD;
             (DPP-4) inhibitors, sodium/glucose co-transporter 2 (SGLT2) inhibitors or weight loss&#xD;
             medications (prescription or OTC) stopped for at least 4 weeks&#xD;
&#xD;
          -  Prior use of medication to treat diabetes except gestational diabetes&#xD;
&#xD;
          -  Eating disorders (anorexia, bulimia) or gastrointestinal disorders&#xD;
&#xD;
          -  Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy in&#xD;
             next 15 months, breastfeeding, or known pregnancy in last three months&#xD;
&#xD;
          -  Active or prior history of substance abuse (smoke or tobacco use within past 6 months)&#xD;
             or significant intake of alcohol&#xD;
&#xD;
          -  Previous bariatric surgery or device intervention for obesity&#xD;
&#xD;
          -  Patient not willing to use barrier contraception during study period (unless&#xD;
             sterilized or have an IUD)&#xD;
&#xD;
          -  History of major depressive or other severe psychiatric disorders&#xD;
&#xD;
          -  Inability or refusal to comply with protocol&#xD;
&#xD;
          -  Currently participating or having participated in an experimental drug study in&#xD;
             previous three months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients must be female to have the disorder being studied since it involved the female reproductive system</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peggy Dean, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Woman's Hospital Foundation IRB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <results_first_submitted>April 14, 2021</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2021</results_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Scientific Director of Research</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>PCOS</keyword>
  <keyword>GLP-1 agonist</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03480022/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03480022/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>88 recruited, 82 met criteria and randomized Six excluded after consenting</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide Pen Injector (Saxenda)</title>
          <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Liraglutide Pen Injector</title>
          <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication concerns</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family member COVID exposure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide Pen Injector (Saxenda)</title>
          <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Liraglutide Pen Injector</title>
          <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="6"/>
                    <measurement group_id="B2" value="31.8" spread="5.6"/>
                    <measurement group_id="B3" value="31.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass Index</title>
          <description>BMI is calculated as kg/meters squared</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="6.7"/>
                    <measurement group_id="B2" value="43.9" spread="7.5"/>
                    <measurement group_id="B3" value="42.4" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Body Weight (BW)</title>
        <description>Treatment impact on change in body weight after 32 weeks of treatment.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Body Weight (BW)</title>
          <description>Treatment impact on change in body weight after 32 weeks of treatment.</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" spread="2.9"/>
                    <measurement group_id="O2" value="117.9" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Androgen Index (FAI)</title>
        <description>Drug treatment effect on free androgen levels as calculated as FAI= total testosterone (T) concentrations divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome (more androgenic).</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Free Androgen Index (FAI)</title>
          <description>Drug treatment effect on free androgen levels as calculated as FAI= total testosterone (T) concentrations divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome (more androgenic).</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="0.6"/>
                    <measurement group_id="O2" value="6.4" spread=".75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.006</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>Treatment effect in reducing body mass</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Treatment effect in reducing body mass</description>
          <units>kilogram/meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="1.1"/>
                    <measurement group_id="O2" value="43.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures nested design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Body Weight</title>
        <description>Treatment effect on reducing body weight expressed as percent body weight loss from baseline</description>
        <time_frame>Change from baseline (time 0) to study end (32 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Body Weight</title>
          <description>Treatment effect on reducing body weight expressed as percent body weight loss from baseline</description>
          <units>percentage loss in body weight</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.75"/>
                    <measurement group_id="O2" value="1.4" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <method>ANOVA</method>
            <method_desc>one-way ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5% Weight Loss From Baseline</title>
        <description>Frequency of patients achieving 5% weight loss from baseline with treatment</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>5% Weight Loss From Baseline</title>
          <description>Frequency of patients achieving 5% weight loss from baseline with treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>10% Body Weight Loss From Baseline</title>
        <description>Frequency of patients with at least 10% reduction in body weight from baseline</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>10% Body Weight Loss From Baseline</title>
          <description>Frequency of patients with at least 10% reduction in body weight from baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.049</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Adiposity (Waist Circumference [WC]</title>
        <description>Treatment effect on loss of WC (abdominal adiposity) with drug treatment</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Adiposity (Waist Circumference [WC]</title>
          <description>Treatment effect on loss of WC (abdominal adiposity) with drug treatment</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.9" spread="2.0"/>
                    <measurement group_id="O2" value="109.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.011</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-Hip Ratio</title>
        <description>Change in central adiposity with treatment as measured by WHR. A reduction in ratio indicates a decrease in truncal fat.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-Hip Ratio</title>
          <description>Change in central adiposity with treatment as measured by WHR. A reduction in ratio indicates a decrease in truncal fat.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.009"/>
                    <measurement group_id="O2" value="0.85" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.038</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to Height Ratio [WHtR])</title>
        <description>Treatment effect on loss of central adiposity as determined by WHt ratio. The lower the ratio indicates less abdominal adiposity.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to Height Ratio [WHtR])</title>
          <description>Treatment effect on loss of central adiposity as determined by WHt ratio. The lower the ratio indicates less abdominal adiposity.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.014"/>
                    <measurement group_id="O2" value="0.67" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.048</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fat Mass Evaluated by DEXA</title>
        <description>Treatment effect on reduction of fat mass (kg)</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fat Mass Evaluated by DEXA</title>
          <description>Treatment effect on reduction of fat mass (kg)</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="2.1"/>
                    <measurement group_id="O2" value="56.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.018</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Fat (%) by DXA</title>
        <description>Treatment effect on reduction of percent body fat by DXA</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Fat (%) by DXA</title>
          <description>Treatment effect on reduction of percent body fat by DXA</description>
          <units>percent fat mass</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="0.9"/>
                    <measurement group_id="O2" value="47.9" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.028</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Android-Gynoid Ratio (AGR) by DXA</title>
        <description>Treatment impact on AGR, measure of central adiposity, as determined by DXA. A lower AGR indicates a reduction in central adiposity.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Android-Gynoid Ratio (AGR) by DXA</title>
          <description>Treatment impact on AGR, measure of central adiposity, as determined by DXA. A lower AGR indicates a reduction in central adiposity.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.01"/>
                    <measurement group_id="O2" value="1.08" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.034</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trunk/Leg Fat Ratio (TLR) by DXA</title>
        <description>Treatment impact on TLR after 32 weeks. A reduction in TLR indicates a loss of central fat.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Trunk/Leg Fat Ratio (TLR) by DXA</title>
          <description>Treatment impact on TLR after 32 weeks. A reduction in TLR indicates a loss of central fat.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.03"/>
                    <measurement group_id="O2" value="1.07" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Menstrual Cycle Frequency</title>
        <description>Drug treatment impact on normalization of cycle frequency (cycle every 28-30 days). All cycle data is expressed as number of menses annualized to one year.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Menstrual Cycle Frequency</title>
          <description>Drug treatment impact on normalization of cycle frequency (cycle every 28-30 days). All cycle data is expressed as number of menses annualized to one year.</description>
          <units>menses per year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="0.4"/>
                    <measurement group_id="O2" value="4.8" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone Concentrations (T)</title>
        <description>Drug treatment effect on total testosterone concentrations</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone Concentrations (T)</title>
          <description>Drug treatment effect on total testosterone concentrations</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="3.0"/>
                    <measurement group_id="O2" value="46.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adrenal Dehydroepiandrosterone Sulfate (DHEAS)</title>
        <description>Treatment efficacy in reducing adrenal hyperandrogenism</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adrenal Dehydroepiandrosterone Sulfate (DHEAS)</title>
          <description>Treatment efficacy in reducing adrenal hyperandrogenism</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.1" spread="14.2"/>
                    <measurement group_id="O2" value="171.3" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose (FG)</title>
        <description>Treatment effect on fasting glucose prior to an oral glucose tolerance test (OGTT)</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose (FG)</title>
          <description>Treatment effect on fasting glucose prior to an oral glucose tolerance test (OGTT)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="1.3"/>
                    <measurement group_id="O2" value="94.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.021</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT Mean Blood Glucose (MBG)</title>
        <description>Treatment effect on MBG measured during the oral glucose tolerance test. A decrease in MBG shows improvement in glycemia.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT Mean Blood Glucose (MBG)</title>
          <description>Treatment effect on MBG measured during the oral glucose tolerance test. A decrease in MBG shows improvement in glycemia.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.4" spread="2.9"/>
                    <measurement group_id="O2" value="125.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.009</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
        <description>Treatment effect on the HOMA-IR which is an insulin resistance measured derived from fasting blood glucose and insulin . The higher the number the more insulin resistant.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
          <description>Treatment effect on the HOMA-IR which is an insulin resistance measured derived from fasting blood glucose and insulin . The higher the number the more insulin resistant.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.6"/>
                    <measurement group_id="O2" value="5.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Insulin Sensitivity Index Derived From the OGTT (SI OGTT)</title>
        <description>The SI OGTT is a measure of peripheral insulin sensitivity derived from the insulin and glucoses measured during an OGTT. A increase in SI OGTTindicates greater insulin sensitivity</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Insulin Sensitivity Index Derived From the OGTT (SI OGTT)</title>
          <description>The SI OGTT is a measure of peripheral insulin sensitivity derived from the insulin and glucoses measured during an OGTT. A increase in SI OGTTindicates greater insulin sensitivity</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.43"/>
                    <measurement group_id="O2" value="3.0" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.028</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</title>
        <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</title>
          <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.18"/>
                    <measurement group_id="O2" value="0.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.042</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion- Insulin Sensitivity Index (Oral Disposition Index-IS-SI)</title>
        <description>Treatment effect on an estimation of Beta cell compensatory function, the IS-SI is derived by applying the concept of the disposition index to measurements obtained during the 2 hour OGTT and calculated as the index of insulin secretion factored by insulin sensitivity. A higher score shows improved pancreatic beta cell function relative to insulin sensitivity.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion- Insulin Sensitivity Index (Oral Disposition Index-IS-SI)</title>
          <description>Treatment effect on an estimation of Beta cell compensatory function, the IS-SI is derived by applying the concept of the disposition index to measurements obtained during the 2 hour OGTT and calculated as the index of insulin secretion factored by insulin sensitivity. A higher score shows improved pancreatic beta cell function relative to insulin sensitivity.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532" spread="91"/>
                    <measurement group_id="O2" value="416" spread="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.033</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Levels</title>
        <description>Treatment impact on improving total cholesterol levels</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Levels</title>
          <description>Treatment impact on improving total cholesterol levels</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="5.3"/>
                    <measurement group_id="O2" value="178" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Impact of treatment on HDL levels after 32 weeks of treatment</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Impact of treatment on HDL levels after 32 weeks of treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="1.8"/>
                    <measurement group_id="O2" value="42" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride Levels (TRG)</title>
        <description>Drug effect of TRG levels after treatment</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Levels (TRG)</title>
          <description>Drug effect of TRG levels after treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="7.7"/>
                    <measurement group_id="O2" value="114" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.016</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride to HDL-Cholesterol Ratio (TRG/HDL-C)</title>
        <description>Treatment impact on TRG/HDL-C ratio which is a simple measure to estimate insulin action. A decrease in ratio indicates improvement in insulin sensitivity.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride to HDL-Cholesterol Ratio (TRG/HDL-C)</title>
          <description>Treatment impact on TRG/HDL-C ratio which is a simple measure to estimate insulin action. A decrease in ratio indicates improvement in insulin sensitivity.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.26"/>
                    <measurement group_id="O2" value="3.0" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.028</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride and Glucose Index (TyG)</title>
        <description>Treatment impact on the TyG index which estimates insulin resistance. A reduction in TyG indicates an improvement in insulin action.</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride and Glucose Index (TyG)</title>
          <description>Treatment impact on the TyG index which estimates insulin resistance. A reduction in TyG indicates an improvement in insulin action.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="0.07"/>
                    <measurement group_id="O2" value="8.5" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Treatment impact on systolic blood pressure</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Treatment impact on systolic blood pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.8" spread="2.7"/>
                    <measurement group_id="O2" value="123.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure (BP)</title>
        <description>Treatment impact on reducing diastolic blood pressure</description>
        <time_frame>32 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide Pen Injector (Saxenda)</title>
            <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Liraglutide Pen Injector</title>
            <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure (BP)</title>
          <description>Treatment impact on reducing diastolic blood pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="1.6"/>
                    <measurement group_id="O2" value="78.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures general linear model (SS/drug treatments by visits) where arm of drug therapy as between subjects effect and visit (baseline and 32 weeks of treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide Pen Injector (Saxenda)</title>
          <description>Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily&#xD;
Liraglutide Pen Injector [Saxenda]: daily sc injection of liraglutide with final dose of 3mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Liraglutide Pen Injector</title>
          <description>Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily&#xD;
Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prolonged menstrual bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>no menses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Research</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>12252315278</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

